Clinical trials: Resolution of Inflammation
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients-1
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-1 (NCT03377790)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 18 sites in United States
- Volunteers
- 266 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Pterygium, Pain
Effect of Bromfenac on Pain Related to Pterygium Surgery
To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution (bromfenac) 0.1% dosed twice daily for the treatment of ocular inflammation and pain after pterygium excision with amniotic membrane transplantation(AMT).
- Trial name
- NCT04022811
- Testing
- 0.1% bromfenac
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Bacteremia, Neoplasms
Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia
Children with cancer need a long term tunnelled central venous catheter (TCVC) for the entire duration of their treatment. TCVCs are locked with heparin when not in use.
- Trial name
- NCT00735813
- Testing
- Taurolock, Heparin
- Where
- Denmark
- Volunteers
- 129 people
- Sponsor
- Aarhus University Hospital
Skin and Soft Tissue Infections, Abscess
The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)
The purpose of this study was to determine whether Irrisept can effectively prevent the progression of skin and soft tissue infections (SSTIs) as compared to treatment by the current Standard of Care.
- Trial name
- NCT01076049
- Testing
- Standard of Care (SoC), Irrisept Delivery System
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Irrimax Corporation
Pseudophakia, Inflammation
Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Investigate the intraocular pressure(pressure inside the eye) of patients who are treated with Lotemax after undergoing cataract surgery.
- Trial name
- NCT01344226
- Testing
- loteprednol 0.5% ophthalmic solution
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Toyos Clinic
Colorectal Cancer
The Role of Lipid Transporter MFSD2A in the Resolution of Colorectal Cancer-associated Inflammation
The intrinsic connection between inflammation and tumor promotion is well characterized and is a key pathogenic event in patients with colorectal cancer (CRC), the second most common cause of tumor-related death in western…
- Trial name
- NCT06071598
- Testing
- Surgical specimens of CRC-affected patients
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- IRCCS San Raffaele
Cataracts
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
To evaluate the safety and efficacy of Nepafenac 1 mg/ml Eye Drops, Suspension, compared to Placebo and Ketorolac Trometamol 5 mg/ml Eye Drops, Solution for the prevention and treatment of ocular inflammation and ocular pain…
- Trial name
- NCT00405730
- Testing
- Nepafenac 1mg/ml eye drops, suspension, Ketorolac Trometamol 5 mg/ml eye drops, solution, Nepafenac vehicle eye drops
- Where
- France
- Volunteers
- 227 people
- Sponsor
- Alcon Research
Inflammation
Pilot Study to Validate ex Vivo Expression of Specific Biomarkers of Human Resolutive Macrophages
Human resolutive macrophages are essential immune cells in the resolution of inflammation. This particular type of macrophages remains poorly known and currently there are no biomarkers to identify them in vivo.
- Trial name
- RESOMACRO (NCT05106075)
- Testing
- blood sample or joint fluid or gingival exudate
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Treatment of Ocular Inflammation Associated With Cataract Surgery
Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (nepafenac Ophthalmic Suspension) 0.3% QD with extra (pulse) dose on day of surgery for Treatment of Ocular Inflammation Associated with Cataract…
- Trial name
- NCT03886779
- Testing
- Bromfenac, Nepafenac
- Volunteers
- 57 people
- Sponsor
- Silverstein Eye Centers
Obesity, Chronic Inflammation
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)
Omega-3 fatty acids, especially EPA and DHA have long been acknowledged for their capacity to counteract inflammatory responses in the human body.
- Trial name
- EPICO (NCT05068557)
- Testing
- Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g)., Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).
- Where
- Mexico
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Guadalajara
Pain, Inflammation
Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
This is an efficacy study of Bromfenac Ophthalmic Solution in cataract surgery.
- Conditions
- Pain, Inflammation, Cataract
- Trial name
- NCT01367249
- Testing
- Bromfenac Ophthalmic Solution
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Bausch & Lomb Incorporated
COPD, Chronic Obstructive Pulmonary Disease
Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD
The symptoms associated with COPD include overproduction of mucus and inflammation in the lungs. Overproduction of mucus results in impaired lung function and it encourages bacterial growth and associated COPD exacerbations.
- Trial name
- BREATH-1 (NCT00648245)
- Testing
- BIO-11006 Inhalation Solution, BIO-11006
- Where
- 14 sites in United States
- Volunteers
- 172 people
- Sponsor
- BioMarck Pharmaceuticals, Ltd.
Sepsis, Acute Kidney Injury
Comparison of Balanced Crystalloids and Normal Saline in Septic Patients
In this prospective randomized controlled trial, investigators attempt to study the effects of acetated Ringer's solution on the prognosis and renal function of patients with sepsis in intensive care unit compared with normal…
- Conditions
- Sepsis, Acute Kidney Injury, Septic Shock, Sepsis, Severe
- Trial name
- NCT03685214
- Testing
- 0.9% saline, lactated Ringer's solution
- Where
- China
- Volunteers
- 500 people
- Sponsor
- ZhiYong Peng
Cataract Surgery
Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery
This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.
- Trial name
- NCT04316936
- Testing
- Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Silverstein Eye Centers
Atopic Keratoconjunctivitis
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC.
- Trial name
- NCT07395232
- Testing
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Where
- 19 sites in United States, Italy and 1 more
- Volunteers
- 153 people
- Sponsor
- Dompé Farmaceutici S.p.A
Meibomian Gland Dysfunction (MGD)
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes.
- Trial name
- NCT07224529
- Testing
- Vevye(Cyclosporine 0.1% Ophthalmic Solution)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Alabama at Birmingham
Inflammation, Cataract
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Study to evaluate the safety and tolerability of PRO-155 Ophthalmic Solution 0.09 % in healthy volunteers.
- Trial name
- PRO-155 (NCT01535443)
- Testing
- Bromfenac
- Where
- Mexico
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Periodontitis
Role of Macrophage in Inflammation Resolution in Periodontal Patients
There is a growing body of evidence to suggest that the resolution of an inflammatory reaction is an active process. This process requiring signals that turn off early inflammatory stages, as neutrophil infiltration and promote…
- Trial name
- NCT01379950
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Postoperative Complications, Cataract
Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery
The primary objective of this study was to investigate the efficacy of bromfenac sodium ophthalmic solution 0.09% for treatment of post-operative ocular inflammation in subjects who undergo cataract extraction and intraocular…
- Trial name
- NCT00198445
- Testing
- Bromfenac
- Where
- 39 sites in United States
- Volunteers
- 527 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Rhinitis
Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With AR. RinASol- Pilot Study
The main objective of RinASol project is to assess in patients with seasonal Allergic Rhinitis the effect of hypertonic saline solution NACL 3%+NAHCO3 vs the effect of standard saline solution on nasal inflammation by means of…
- Trial name
- RinASol (NCT02729012)
- Testing
- hypertonic saline solution (NACL 3%+NAHCO3), Saline Solution (NACL 0,9%)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Stefania La Grutta, MD